Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Standard

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. / Raj, Kavita; Eikema, Diderik-Jan; McLornan, Donal P; Olavarria, Eduardo; Blok, Henric-Jan; Bregante, Stefania; Ciceri, Fabio; Passweg, Jakob; Ljungman, Per; Schaap, Nicolaas; Carlson, Kristina; Zuckerman, Tsila; de Wreede, Liesbeth C; Volin, Liisa; Koc, Yener; Diez-Martin, Jose Luis; Brossart, Peter; Wolf, Dominik; Blaise, Didier; Bartolomeo, Paolo Di; Vitek, Antonin; Robin, Marie; Yakoub-Agha, Ibrahim; Chalandon, Yves; Kroger, Nicolaus.

in: BIOL BLOOD MARROW TR, Jahrgang 25, Nr. 3, 03.2019, S. 522-528.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

Raj, K, Eikema, D-J, McLornan, DP, Olavarria, E, Blok, H-J, Bregante, S, Ciceri, F, Passweg, J, Ljungman, P, Schaap, N, Carlson, K, Zuckerman, T, de Wreede, LC, Volin, L, Koc, Y, Diez-Martin, JL, Brossart, P, Wolf, D, Blaise, D, Bartolomeo, PD, Vitek, A, Robin, M, Yakoub-Agha, I, Chalandon, Y & Kroger, N 2019, 'Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation', BIOL BLOOD MARROW TR, Jg. 25, Nr. 3, S. 522-528. https://doi.org/10.1016/j.bbmt.2018.10.017

APA

Vancouver

Bibtex

@article{485632c745f3417d92d868a0e2d0c45f,
title = "Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation",
abstract = "This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75{\%} had primary MF and 25{\%} had secondary MF. JAK2 V617F was mutated in 61{\%}. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66{\%} and peripheral blood in 34{\%}. The median CD34+ cell dose was 4.8 × 106/kg (range, 1.7 to 22.9; n = 43). Conditioning was predominantly myeloablative in 70{\%} and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59{\%}. The incidence of neutrophil engraftment by 28 days was 82{\%} (range, 70{\%} to 93{\%}), at a median of 21 days (range, 19 to 23). At 2 years the cumulative incidence of primary graft failure was 9{\%} (95{\%} CI 1{\%} to 16{\%}) and secondary graft failure was 13{\%} (95{\%} CI 4{\%} to 22{\%}). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28{\%} (95{\%} CI 16{\%} to 40{\%}) and 9{\%} (95{\%} CI 2{\%} to 17{\%}) at 100 days. The cumulative incidence of chronic GVHD at 1 year was 45{\%} (95{\%} CI 32{\%} to 58{\%}), but the cumulative incidence of death without chronic GVHD by 1 year was 20{\%} (95{\%} CI 10{\%} to 31{\%}). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61{\%} (95{\%} CI 48{\%} to 74{\%}) and 56{\%} (95{\%} CI 41{\%} to 70{\%}), respectively. The 1- and 2- year progression-free survival was 58{\%} (95{\%} CI 45{\%} to 71{\%}) and 43{\%} (95{\%} CI 28{\%} to 58{\%}), respectively, with a 2-year cumulative incidence of relapse of 19{\%} (95{\%} CI 7{\%} to 31{\%}). The 2-year nonrelapse mortality was 38{\%} (95{\%} CI 24{\%} to 51{\%}). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80{\%} of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion.",
keywords = "Journal Article",
author = "Kavita Raj and Diderik-Jan Eikema and McLornan, {Donal P} and Eduardo Olavarria and Henric-Jan Blok and Stefania Bregante and Fabio Ciceri and Jakob Passweg and Per Ljungman and Nicolaas Schaap and Kristina Carlson and Tsila Zuckerman and {de Wreede}, {Liesbeth C} and Liisa Volin and Yener Koc and Diez-Martin, {Jose Luis} and Peter Brossart and Dominik Wolf and Didier Blaise and Bartolomeo, {Paolo Di} and Antonin Vitek and Marie Robin and Ibrahim Yakoub-Agha and Yves Chalandon and Nicolaus Kroger",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "3",
doi = "10.1016/j.bbmt.2018.10.017",
language = "English",
volume = "25",
pages = "522--528",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

AU - Raj, Kavita

AU - Eikema, Diderik-Jan

AU - McLornan, Donal P

AU - Olavarria, Eduardo

AU - Blok, Henric-Jan

AU - Bregante, Stefania

AU - Ciceri, Fabio

AU - Passweg, Jakob

AU - Ljungman, Per

AU - Schaap, Nicolaas

AU - Carlson, Kristina

AU - Zuckerman, Tsila

AU - de Wreede, Liesbeth C

AU - Volin, Liisa

AU - Koc, Yener

AU - Diez-Martin, Jose Luis

AU - Brossart, Peter

AU - Wolf, Dominik

AU - Blaise, Didier

AU - Bartolomeo, Paolo Di

AU - Vitek, Antonin

AU - Robin, Marie

AU - Yakoub-Agha, Ibrahim

AU - Chalandon, Yves

AU - Kroger, Nicolaus

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/3

Y1 - 2019/3

N2 - This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106/kg (range, 1.7 to 22.9; n = 43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28 days was 82% (range, 70% to 93%), at a median of 21 days (range, 19 to 23). At 2 years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100 days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion.

AB - This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106/kg (range, 1.7 to 22.9; n = 43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28 days was 82% (range, 70% to 93%), at a median of 21 days (range, 19 to 23). At 2 years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100 days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion.

KW - Journal Article

U2 - 10.1016/j.bbmt.2018.10.017

DO - 10.1016/j.bbmt.2018.10.017

M3 - SCORING: Journal articles

C2 - 30408564

VL - 25

SP - 522

EP - 528

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 3

ER -